Goals; Per the shareholder's letter from Septem
Post# of 154836
(Total Views: 552)
Posted On: 12/05/2024 11:18:45 AM
Goals;
Per the shareholder's letter from September 9, 2024:
We (investors) are to expect updates for the upcoming phase two CRC trial, which should start screening patients in early 2025.
We are to expect updates on the progress of designing a preclinical TNBC trial that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors. The Company intends to use this preclinical study to form the basis for a potential partnership and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
We are to expect the results from the preclinical Glioblastoma study in mice performed by the Albert Einstein College of Medicine should be released in the coming months.
https://www.cytodyn.com/newsroom/press-releas...areholders
It has been nearly three months, since our last share holder update. I'm thinking we should get an update, possibly, next week. We are due some information. I am excited to hear about more progress! I liked the letter format.
Per the shareholder's letter from September 9, 2024:
We (investors) are to expect updates for the upcoming phase two CRC trial, which should start screening patients in early 2025.
We are to expect updates on the progress of designing a preclinical TNBC trial that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors. The Company intends to use this preclinical study to form the basis for a potential partnership and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
We are to expect the results from the preclinical Glioblastoma study in mice performed by the Albert Einstein College of Medicine should be released in the coming months.
https://www.cytodyn.com/newsroom/press-releas...areholders
It has been nearly three months, since our last share holder update. I'm thinking we should get an update, possibly, next week. We are due some information. I am excited to hear about more progress! I liked the letter format.
(9)
(0)